1-6 of 6
Phillip Liu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Mechanisms of the Anti-Tumor Activity of STAT3 Degraders in Lymphoma

Haojing Rong, PhD, Kirti Sharma, Fred Csibi, Bin Yang, Scott Rusin, Yatao Shi, PhD, Joyoti Dey, PhD, Rahul Karnik, Michele Mayo, Karen Yuan, Yogesh Chutake, Alice McDonald, PhD, Sean Zhu, PhD, Nan Ji, PhD, Phillip Liu, PhD, Henry Li, PhD, Duncan Walker, PhD, Jared Gollob, PhD MD, Nello Mainolfi, PhD, Chris Desavi
Journal: Blood
Blood (2020) 136 (Supplement 1): 42.
https://doi.org/10.1182/blood-2020-137778
Published: 2020
Journal Articles

Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a

Christopher Letson, BS, Alexis Vedder, BS, Ariel Quintana, PhD, Phillip Liu, PhD, Brett Reid, Maria E Balasis, Hannah Newman, BS, Traci Kruer, PhD, Luciana L Almada, PhD, Guolin Zhang, PhD, Martin Fernandez-Zapico, MD, Mrinal M Patnaik, MDMBBS, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, P.K. Epling-Burnette, PharmD, PhD, Alan F. List, MD, Eric B. Haura, MD, Gary W. Reuther, Thomas A. Sellers, PhD, Holly K. Koblish, PhD, Eric Padron, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4220.
https://doi.org/10.1182/blood-2019-128165
Published: 2019
Journal Articles

The BET Inhibitor INCB054329 Primes AML Cells for Venetoclax-Induced Apoptosis

Haley Ramsey, PhD MSc, Susu Zhang, Yue Zhao, PhD, Melissa Ann Fischer, PhD, Agnieszka Ewa Gorska, MSc, Maria Arrate, MSc, Londa Fuller, Dalton Greenwood, Matthew C. Stubbs, PhD, Phillip Liu, PhD, Jeffrey C Rathmell, PhD, Scott Hiebert, PhD, Michael R. Savona, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4074.
https://doi.org/10.1182/blood-2018-99-111393
Published: 2018
Journal Articles

High Resolution Mapping of Active RNA Polymerases Identifies KIT As a Target of BET Inhibitors in t(8;21) AML

Yue Zhao, PhD, Phillip Liu, PhD, Peggy Scherle, PhD, Reid Huber, PhD, Michael R. Savona, MD, Scott Hiebert, PhD
Journal: Blood
Blood (2015) 126 (23): 1225.
https://doi.org/10.1182/blood.V126.23.1225.1225
Published: 2015
Journal Articles

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

Alfonso Quintás-Cardama, Kris Vaddi, Phillip Liu, Taghi Manshouri, Jun Li, Peggy A. Scherle, Eian Caulder, Xiaoming Wen, Yanlong Li, Paul Waeltz, Mark Rupar, Timothy Burn, Yvonne Lo, Jennifer Kelley, Maryanne Covington, Stacey Shepard, James D. Rodgers, Patrick Haley, Hagop Kantarjian, Jordan S. Fridman, Srdan Verstovsek
Journal: Blood
Blood (2010) 115 (15): 3109–3117.
https://doi.org/10.1182/blood-2009-04-214957
Published: 2010
Includes: Supplemental data
Journal Articles

Discovery and Preclinical Characterization of INCB018424, a Selective JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders.

Jordan Fridman, PhD, Roberto Nussenzveig, PhD, Phillip Liu, PhD, James Rodgers, PhD, Timothy Burn, PhD, Patrick Haley, DVM, Peggy Scherle, PhD, Robert Newton, PhD, Gregory Hollis, PhD, Steven Friedman, MD, Srdan Verstovsek, MD, PhD, Kris Vaddi, PhD
Journal: Blood
Blood (2007) 110 (11): 3538.
https://doi.org/10.1182/blood.V110.11.3538.3538
Published: 2007